The general director of Pfizer Spain, Sergio Rodríguez, has assured that the Pfizer-BioNTech vaccine, which is the one that is being supplied from this Sunday in Spain, “it is safer and easily adaptable to virus mutations“as it has been developed with” a new technology “.
As explained this Sunday in an interview for RTVE collected by Europa Press, the technology on which this vaccine is based – on messenger RNA – makes that it provides instructions to cells to generate antigens without the need to inoculate the virus, contrary to what happens with traditional vaccines, in which the weakened virus or part of the virus is inoculated so that antibodies are generated.
In this sense, Rodríguez affirms that “no vaccine had been developed with this technology”, which is also “safe” and “effective”, as has been shown in trials to date, 44,000 people worldwide. Although, the general director of Pfizer Spain indicates that the trial has not yet finished and that it will end in the next two years.
The speed with which the Pfizer-BioNTech vaccine has arrived has been due, according to Rodríguez, to multiple factors, including collaboration between scientists, universities and public administrations or the regulatory agencies themselves, which have accelerated the processes. Further, Rodríguez attributes “part of the success” of this vaccine to the high incidence of COVID-19, which has allowed trials to be accelerated and production to start “at risk,” that is, before the vaccine was approved.
The Pfizer-BioNTech vaccine has a special feature: it has to be transported at -70ºC. “The reason why it has to be at -70ºC is because it is very effective that way, that is why the vaccine is transported in special packages with dry ice, for at least 30 days,” Rodríguez explained.
As he adds, all packages have a traceability device (GPS) and a temperature controller to ensure that the cold chain is not lost. Afterwards, once the vaccine comes out of the packaging, it can be kept in a normal refrigerator at a temperature between 2ºC and 8ºC for 5 days, but if it is put in a deep freezer it can last up to 6 months. “All this technology has been developed to facilitate that it can reach all patients during the vaccination period that is necessary,” he says.
During the interview, Rodríguez announced that The company continues to work on trials so that during the first quarter of 2022 the vaccine can be lyophilized, in order to make transport easier.
Given the transportation difficulties, the CEO of Pfizer Spain has defended that the company is working to make the vaccine accessible and can be distributed throughout the world. “We need coverage of the entire population, it is not enough that there is only coverage in Spain,” he recalls.
Digsmak is a news publisher with over 12 years of reporting experiance; and have published in many industry leading publications and news sites.